First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent

Anticancer Research

Volumn 26, Issue 4 B, 2006, Pages 2841-2848

  Jonasdottir, Thora J ^a   Fisher, Darrell R ^b   Borrebæk, Jørgen ^c   Bruland, Øyvind S ^d,e   Larsen, Roy H ^c  

^a NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^b PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^c Algeta ASA   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Alpha emitting 223Ra; In vivo evaluation; Pegylated liposomes

Indexed keywords

CHLORIDE; DOXORUBICIN; LIPOSOME; RADIOISOTOPE; RADIUM; RADIUM 223; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE; CATABOLISM; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE;

ALPHA PARTICLES; ANIMALS; DOXORUBICIN; FEMALE; HALF-LIFE; MALE; MICE; MICE, INBRED BALB C; POLYETHYLENE GLYCOLS; RADIUM; TISSUE DISTRIBUTION;

EID: 33746672008     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. 211At-labeled antibodies for clinical use. J Nucl Med 42: 1508-1515, 2001.
2. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Harnacher KA, Ma D, Humm JL, Brechbiel MV, Molinet R and Scheinberg DA: Targeted α-particulate immunotherapy for myeloid leukemia. Blood 100: 1233-1239, 2002.
3. Nilsson S, Larsen RH, Fossa SD, Baltesgard L, Borch KW, Westlin JE, Salberg G and Bruland OØS: First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases, Clin Cancer Res 11: 4451-4459, 2005.
4. 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res, in press, 2006.
5. Henriksen G, Hoff P and Larsen RH: Evaluation of potential chelating agents for radium. Appl Rad Isot 56: 667-671, 2002.
6. Gabizon AA: Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 7: 223-225, 2001.
7. Henriksen G, Schoultz BW, Michaelsen TE, Bruland ØS and Larsen RH: Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides. Nucl Med Biol 31: 441-449, 2004.
8. 227Th source. Radiochim Acta 89: 661-666, 2001.
9. 89Sr in mice. J Nucl Med 44: 252-259, 2003.
10. Fisher DR and Harty R: The microdosimetry of lymphocytes irradiated by alpha particles. Int J Radiat Biol 41: 315-324, 1982.
11. Gabizon A, Tzemach D, Mak L, Bronstein M and Horowitz AT: Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 10: 539-548, 2002.
12. Gabizon A, Shmeeda H and Barenholz Y: Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42: 419-436, 2003.
13. Nilsson S, Larsen RH, Fossa SD, Baltesgard L, Borch KW, Westlin JE, Salberg G and Bruland ØS: First clinical experience with Ø-emitting radium-223 in the treatment of skeletal métastases. Clin Cancer Res 11: 4451-4459, 2005.
14. 223Ra injected intraveneously into mice: histology, clinical chemistry and hematology. In Vivo 20: 325-332, 2006.
15. 212Bi. Radiochim Acta 91: 109-113, 2003.
16. Sofou S, Thomas JL, Lin HY, McDevitt MR, Scheinberg DA and Sgouros G: Engineered liposomes for potential alpha-particle therapy of metastatic cancer. J Nucl Medic 45: 253-260, 2004.
17. Ando A, Ando I, Hiraki T and Hisada K: Relation between the location of elements in the periodic table and various organ-uptake rates. Nucl Med Biol 1: 57-80, 1989.